WATERTOWN, Mass., Feb. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 49,000 s ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

EyePoint Pharmaceuticals (EYPT) closed the last trading session at $29.71, gaining 30.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39 indicates a 31.3% upside potential.The average comprises eight short-term price targets ranging from a low of $30 to a high of $55, with a standard deviation of $8.82. While the lowest estimate indicates an increase of 1% from the current pric ...

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were metResults presented today at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting WATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from _______ to _______ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 000-51122 For the quarterly period ended September 30, 2023 EyePoint Pharmaceuticals, Inc. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Zip Code) (617) 926-5000 (Registrant's telephone number, including area code) (Fo ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Conference Call Participants Tyler Van Buren - Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Daniel Catalin - Chardan Sean Kim - Jones Trading Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright & Company Operator Good morning. My name is Leeway and I will be your conference operator today. At this time, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdi ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2023 Earnings Call Transcript August 2, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Dr. Jay Duker - President, and Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Yatin Suneja - Guggenheim Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan Sean Kim - Jones Trading I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright Operator Good morning. My name is [indiscernibl ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer Dr. Jay Duker - President and Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Yatin Suneja - Guggenheim Tyler Van Buren - Cowen Jennifer Kim - Cantor Fitzgerald Colleen Kusy - Baird Daniel Catalin - Chardan I-Eh Jen - Laidlaw & Co Chaitanya Gollakota - H.C. Wainwright ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 480 Pleasant Street Watertown, MA (Address of principal executive offices) 26-2774444 (I.R.S. Employer Identification No.) 02472 (Zip Code) ☐ TRANSITION REPORT PURS ...